VALLEY FORGE, Pa.--(BUSINESS WIRE)--Jun. 8, 2012--
AmerisourceBergen Corporation (NYSE: ABC) today announced that Lazarus
Krikorian, 47, has been appointed Vice President, Corporate Controller,
effective immediately. Krikorian will be an officer of the Company, and
will report to Tim G. Guttman, who was recently appointed Senior Vice
President and Chief Financial Officer, and whom Krikorian succeeds as
Corporate Controller.
“I am very pleased to promote Laz to his new role,” said Guttman. “He is
a seasoned financial executive who has demonstrated excellent
leadership, including playing a key role in the successful
implementation of our new back-office ERP platform. Laz is also
responsible for overseeing the Company’s internal and external financial
reporting process. He has demonstrated good governance and financial
oversight of the Company’s capital projects, and I am certain that he
will continue to make important contributions to the Company’s future
success.”
Krikorian was previously Vice President, Assistant Corporate Controller,
a position he held since joining AmerisourceBergen in 2002. Prior to
joining the Company, he held other financial management positions,
including Senior Assurance Manager at KPMG LLP, where he spent a decade.
He holds a Bachelor of Science in the dual major of Accounting and
Finance from Drexel University.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from niche
premium logistics and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $80 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 13,000 people. AmerisourceBergen is ranked #29 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These statements are based on management's current expectations
and are subject to uncertainty and change in circumstances. Among the
factors that could cause actual results to differ materially from those
projected, anticipated or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer
or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other dispute with customers or suppliers; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; qui tam litigation for alleged violations of fraud
and abuse laws and regulations and/or any other laws and regulations
governing the marketing, sale and purchase of pharmaceutical products or
services and any related litigation, including shareholder derivative
lawsuits; changes in federal and state legislation or regulatory action
affecting pharmaceutical product pricing or reimbursement policies,
including under Medicaid and Medicare; changes in regulatory or clinical
medical guidelines and/or labeling for the pharmaceutical products we
distribute, including certain anemia products; price inflation in
branded pharmaceuticals and price deflation in generics; greater or less
than anticipated benefit from launches of the generic versions of
previously patented pharmaceutical products; significant breakdown or
interruption of our information technology systems; our inability to
continue to implement an enterprise resource planning (ERP) system to
handle business and financial processes and transactions (including
processes and transactions relating to our customers and suppliers) of
AmerisourceBergen Drug Corporation operations as intended without
functional problems, unanticipated delays and/or cost overruns; success
of integration, restructuring or systems initiatives; interest rate and
foreign currency exchange rate fluctuations; economic, business,
competitive and/or regulatory developments in Canada, the United Kingdom
and elsewhere outside of the United States, including changes and/or
potential changes in Canadian provincial legislation affecting
pharmaceutical product pricing or service fees or regulatory action by
provincial authorities in Canada to lower pharmaceutical product pricing
and service fees; the impact of divestitures or the acquisition of
businesses that do not perform as we expect or that ar
Request Info
Tell a Friend
Print
View printer-friendly version